ELI LILLY & Co stock analysis
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70
- Ticker
- LLY
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Pharmaceuticals
Market evidence and data freshness
The public preview recorded ELI LILLY & Co at 1,388.795 USD on 2026-11-05T18:25:29.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2026-05-11 through 2026-11-04 across 122 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.
Published research mentioning LLY
These are separate dated research reports, not a consensus view or a current signal.
What should I review before buying ELI LILLY & Co stock?
Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.
Inside the full analysis
- Valuation
- Growth
- Financial health
- Ownership
- Research
Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.
Sign in to open the analysis